Reduced Esophageal Contractility Is Associated with Dysplasia Progression in Barrett's Esophagus: A Multicenter Cohort Study.


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
12 2020
Historique:
received: 18 10 2019
accepted: 20 01 2020
pubmed: 7 2 2020
medline: 5 2 2021
entrez: 7 2 2020
Statut: ppublish

Résumé

The incidence of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) continues to rise, and risk stratification of patients with BE is needed. Impaired esophageal motility is associated with gastroesophageal reflux disease; however, whether esophageal dysmotility is a risk factor for dysplasia progression in BE is incompletely understood. This study aimed to characterize esophageal motility patterns in patients with BE and identify physiologic factors associated with dysplasia progression in BE. This multicenter retrospective study assessed data from adult patients with histologically confirmed BE who underwent high-resolution esophageal manometry from 1/2014 to 1/2018 at four tertiary care centers. Longitudinal data were collected when available among patients with non-dysplastic BE (NDBE) and separated as: no dysplastic progression or positive dysplastic progression. Multivariable logistic regression assessed for independent predictors of dysplasia progression. Among 193 patients, histology at index endoscopy identified 152 (79%) NDBE, 23 (12%) low-grade dysplasia, 14 (7%) high-grade dysplasia, and 4 (2%) EAC. Ninety-eight (51%) had abnormal esophageal motor function on manometry. Longitudinal data were available for 84 of 152 patients with initial NDBE. Twelve (14%) exhibited dysplastic progression to low-grade (6) or high-grade (6) dysplasia. Mean esophageal distal contractile integral was lower for patients that progressed [455 mmHg s cm (SD 515)] compared with patients who did not progress [987 mmHg s cm (SD 953); aOR 1.21 (95% CI 1.01, 1.44)]. In this retrospective study of 193 BE patients, the majority exhibited abnormal esophageal motor function. Reduced esophageal contractility was independently associated with dysplastic progression in BE. Characterizing esophageal physiology in BE may help to risk stratify patients.

Sections du résumé

BACKGROUND
The incidence of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) continues to rise, and risk stratification of patients with BE is needed. Impaired esophageal motility is associated with gastroesophageal reflux disease; however, whether esophageal dysmotility is a risk factor for dysplasia progression in BE is incompletely understood. This study aimed to characterize esophageal motility patterns in patients with BE and identify physiologic factors associated with dysplasia progression in BE.
METHODS
This multicenter retrospective study assessed data from adult patients with histologically confirmed BE who underwent high-resolution esophageal manometry from 1/2014 to 1/2018 at four tertiary care centers. Longitudinal data were collected when available among patients with non-dysplastic BE (NDBE) and separated as: no dysplastic progression or positive dysplastic progression. Multivariable logistic regression assessed for independent predictors of dysplasia progression.
RESULTS
Among 193 patients, histology at index endoscopy identified 152 (79%) NDBE, 23 (12%) low-grade dysplasia, 14 (7%) high-grade dysplasia, and 4 (2%) EAC. Ninety-eight (51%) had abnormal esophageal motor function on manometry. Longitudinal data were available for 84 of 152 patients with initial NDBE. Twelve (14%) exhibited dysplastic progression to low-grade (6) or high-grade (6) dysplasia. Mean esophageal distal contractile integral was lower for patients that progressed [455 mmHg s cm (SD 515)] compared with patients who did not progress [987 mmHg s cm (SD 953); aOR 1.21 (95% CI 1.01, 1.44)].
CONCLUSION
In this retrospective study of 193 BE patients, the majority exhibited abnormal esophageal motor function. Reduced esophageal contractility was independently associated with dysplastic progression in BE. Characterizing esophageal physiology in BE may help to risk stratify patients.

Identifiants

pubmed: 32026276
doi: 10.1007/s10620-020-06098-5
pii: 10.1007/s10620-020-06098-5
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

3631-3638

Références

Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett’s esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249–1256.
doi: 10.1016/S0016-5085(89)80011-3
Kestens C, Offerhaus GJ, van Baal JW, Siersema PD. Patients with Barrett’s esophagus and persistent low-grade dysplasia have an increased risk for high-grade dysplasia and cancer. Clin Gastroenterol Hepatol. 2016;14:956.e1–962.e1.
doi: 10.1016/j.cgh.2015.12.027
Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23:3155–3162.
doi: 10.1093/annonc/mds181
Desai M, Lieberman DA, Kennedy KF, et al. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett’s esophagus over the past 2 decades: data from a multicenter U.S. consortium. Gastrointest Endosc. 2018;89:257–263.
doi: 10.1016/j.gie.2018.09.041
Codipilly DC, Chandar AK, Singh S, et al. The effect of endoscopic surveillance in patients with Barrett’s esophagus: a systematic review and meta-analysis. Gastroenterology. 2018;154:2068e5–2086e5.
doi: 10.1053/j.gastro.2018.02.022
Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1046e8–1055e8.
doi: 10.1016/j.cgh.2017.11.044
Thrift AP, Garcia JM, El-Serag HB. A multibiomarker risk score helps predict risk for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12:1267–1271.
doi: 10.1016/j.cgh.2013.12.014
Rubenstein JH, Morgenstern H, Appelman H, et al. Prediction of Barrett’s esophagus among men. Am J Gastroenterol. 2013;108:353–362.
doi: 10.1038/ajg.2012.446
Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett’s esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg. 1999;117:572–580.
doi: 10.1016/S0022-5223(99)70337-5
Helman L, Biccas BN, Lemme EM, Novais P, Fittipaldi V. Esophageal manometry findings and degree of acid exposure in short and long Barrett’s esophagus. Arq Gastroenterol. 2012;49:64–68.
doi: 10.1590/S0004-28032012000100011
Blevins CH, Iyer PG, Vela MF, Katzka DA. The esophageal epithelial barrier in health and disease. Clin Gastroenterol Hepatol. 2018;16:608–617.
doi: 10.1016/j.cgh.2017.06.035
Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160–174.
doi: 10.1111/nmo.12477
Wani S, Gaddam S. Editorial: Best practices in surveillance of Barrett’s esophagus. Am J Gastroenterol. 2017;112:1056–1060.
doi: 10.1038/ajg.2017.117
Parasa S, Vennalaganti S, Gaddam S, et al. Development and validation of a model to determine risk of progression of Barrett’s esophagus to neoplasia. Gastroenterology. 2018;154:1282e2–1289e2.
doi: 10.1053/j.gastro.2017.12.009
Sanagapalli S, Emmanuel A, Leong R, et al. Impaired motility in Barrett’s esophagus: a study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018. https://doi.org/10.1111/nmo.13330 .
Bazin C, Benezech A, Alessandrini M, Grimaud JC, Vitton V. Esophageal motor disorders are a strong and independent associated factor of Barrett’s esophagus. J Neurogastroenterol Motil. 2018;24:216–225.
doi: 10.5056/jnm17090
Farre R, van Malenstein H, De Vos R, et al. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut. 2008;57:1366–1374.
doi: 10.1136/gut.2007.141804
Xiao Y, Kahrilas PJ, Kwasny MJ, et al. High-resolution manometry correlates of ineffective esophageal motility. Am J Gastroenterol. 2012;107:1647–1654.
doi: 10.1038/ajg.2012.286
Kahrilas PJ. Esophageal motor activity and acid clearance. Gastroenterol Clin North Am. 1990;19:537–550.
pubmed: 2228163
Frazzoni M, de Bortoli N, Frazzoni L, et al. The added diagnostic value of postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on-therapy impedance-pH monitoring. Neurogastroenterol Motil. 2017;29.
Patel A, Wang D, Sainani N, Sayuk GS, Gyawali CP. Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2016;44:890–898.
doi: 10.1111/apt.13777
Wang D, Patel A, Mello M, Shriver A, Gyawali CP. Esophagogastric junction contractile integral (EGJ-CI) quantifies changes in EGJ barrier function with surgical intervention. Neurogastroenterol Motil. 2016;28:639–646.
doi: 10.1111/nmo.12757

Auteurs

Rena Yadlapati (R)

Division of Gastroenterology, University of California, San Diego School of Medicine, ACTRI Building 1W517, 9500 Gilman Drive MC 0956, La Jolla, CA, 92093, USA. ryadlapati@ucsd.edu.

Joseph Triggs (J)

Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Farhan Quader (F)

Division of Gastroenterology and Hepatology, Washington University School of Medicine, St. Louis, MO, USA.

Swathi Eluri (S)

Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Shweta Bhatia (S)

Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Alexander Kaizer (A)

Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.

John E Pandolfino (JE)

Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Srinadh Komanduri (S)

Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Prakash Gyawali (P)

Division of Gastroenterology and Hepatology, Washington University School of Medicine, St. Louis, MO, USA.

Nicholas J Shaheen (NJ)

Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Paul Menard-Katcher (P)

Division of Gastroenterology and Hepatology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.

Sachin Wani (S)

Division of Gastroenterology and Hepatology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH